RxDoctor Payments Data

Man-Kit Leung, MD

Otolaryngology · San Francisco, CANPI 1144417007

Payments from drug & device makers

$2,486in general payments, 2019–2025

Across 43 payments — averaging $57.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$297
  • GSK$288
  • Sanofi$271
  • Medtronic$150
  • Intersect ENT, Inc.$100
  • plus $242 from 9 others

What the payments were for

  • Consulting fees$1,05042%
  • Food & beverage$1,43658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,486 in reported general payments places this provider in the 70th percentile of 1,021 otolaryngology providers in California.

See all otolaryngology providers in California

Medicare billing

Part B allowed, 2024
$212,836
Medicare patients
633
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XhanceFluticasone Propionate27$25,799
Azelastine Hcl90$5,129
Fluticasone Propionate213$3,660
Ofloxacin55$3,502
Ipratropium Bromide57$2,674
Fluocinolone Acetonide Oil79$1,906
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth24$1,761
Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid11$874
Triamcinolone Acetonide40$374
Doxycycline Monohydrate21$361
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav40$340
Fluocinonide12$289
Mupirocin41$190
Omeprazole21$138
Montelukast Sodium18$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$1,139$25,79927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,021 otolaryngology providers in California.

Other otolaryngology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →